Armata pharmaceuticals, inc. (APHB)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Revenue

-

-

-

-

-

-

-

-

-

20

38

28

29

22

29

103

106

128

143

102

102

-

103

101

-

-

-

-

22

Revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

104

-252

-3

314

22

Operating expenses
Research and development (benefit)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,655

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

-

-

-

-

-

-

-

-

1,464

1,090

-829

1,130

1,490

-

-

1,241

1,980

1,215

728

1,077

972

1,113

1,793

1,888

1,011

1,110

1,123

3,595

641

Research and development

2,750

-

3,019

3,076

2,061

-

1,915

2,286

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development benefit

-

-

-

-

-

-

-

-

-

-

829

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

General and administrative

2,171

2,045

3,758

2,082

1,380

-143

514

557

1,591

1,295

1,613

2,784

1,898

1,537

1,781

2,451

2,644

1,853

1,843

1,617

1,397

1,561

1,701

1,961

1,627

1,224

1,215

2,843

714

Impairment charges

-

-

-

-

-

-

-

-

-

-

-

5,800

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Severance expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,840

-

-

-

0

-

-

Total operating expenses

-

-

6,777

5,158

-

9,331

2,429

2,843

3,055

2,385

784

9,714

3,388

11,886

3,436

3,692

4,624

3,068

2,571

2,694

2,369

2,698

5,334

3,849

2,638

2,334

2,338

6,438

1,355

Loss from operations

-4,921

-4,376

-6,777

-5,158

-3,441

-9,331

-2,429

-2,843

-3,055

-2,365

-746

-9,686

-3,359

-11,864

-3,407

-3,589

-4,518

-2,940

-2,428

-2,592

-2,267

-2,597

-5,231

-3,748

-2,534

-2,586

-2,341

-6,124

-1,333

Other income (expense)
Interest income

2

7

13

28

48

-

70

58

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of Preferred B stock derivative liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-7,105

-

19,359

12,217

-

-

-

-

-

Other expense, net

-

-

-

-

-

-

-

-

-

-

-

-

1

-

-

227

-

0

-129

0

431

-

-

-

-

-

-

-

-

Other expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Amortization of note discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,334

303

Amortization of note discount and patents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

23

-

-

Interest expense

159

174

190

230

306

-

307

281

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

9

128

96

Other income (expense)

-

-

-1

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income (expense)

-

-

-

4

-

-

-

-

-

-

4

3

-

-

-

-

-

-

129

-

-

-

-

-

-

-

-

-

-

Change in fair value of derivative liabilities

-

0

0

1,157

-40

2,009

-105

-101

-79

13

-37

1,920

114

2,135

1,032

-35

1,406

-6,469

7,738

13,361

-4,690

5,745

7,079

5,404

-8,773

3,020

-46,380

-6,057

87

Total other income (expense), net

-157

-210

-178

959

-298

1,701

-342

-324

-79

13

-33

1,923

113

1,808

1,032

-262

1,406

636

7,867

13,361

-12,226

1,933

26,438

17,621

-8,773

3,044

-46,412

-8,519

-312

Loss before income taxes

-

-

-6,955

-4,199

-

-

-2,771

-3,167

-

-

-779

-7,763

-

-

-2,375

-3,851

-

-

-

-

-

-

-

-

-

-

-

-

-

Income tax benefit

-

-

-

-

-

-

-

-

-

-

-

-1,302

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-5,078

-4,586

-6,955

-4,199

-3,739

-7,630

-2,771

-3,167

-3,134

-2,352

-779

-6,461

-3,246

-9,500

-2,375

-3,851

-3,112

-2,231

5,439

10,769

-14,493

-664

21,207

13,873

-11,307

458

-48,753

-14,643

-1,645

Unrealized gain on investments

-

-

-

-

-

-

-

7

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss

-

-

-6,955

-4,199

-

-

-2,771

-3,160

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Excess of fair value of consideration transferred on conversion of Series B redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,214

-2,366

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of Series B redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

133

1,725

949

7,163

1,828

338

330

323

318

314

229

286

103

0

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-3,246

-9,500

-3,589

-6,350

-4,837

-3,180

-1,724

8,941

-14,831

-7,061

20,884

13,555

-11,621

229

-49,039

-14,746

-1,645

Per share information:
Net loss per share, basic and diluted (in dollars per share)

-0.49

-

-

-

-0.80

-

-

-

-0.24

-

-

-

-1.94

-

-

-

-8.22

-

-

-

-

-

-

-

-0.06

-

-

-

-0.03

Weighted average shares outstanding, basic and diluted

10,451

-

-

-

4,652

-

-

-

13,298

-

-

-

1,677

-

-

-

588

-

-

-

-

-

-

-

182,535

-

-

-

66,908

Net loss

-5,078

-4,586

-6,955

-4,199

-3,739

-7,630

-2,771

-3,167

-3,134

-2,352

-779

-6,461

-3,246

-

-2,375

-3,851

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss per share, basic

-

-

-0.73

-0.56

-

-

-0.60

-0.68

-

-

-0.09

-1.21

-

-

-3.23

-7.26

-

-

-0.30

1.27

-3.49

-

5.58

3.69

-

-

-0.49

-0.16

-

Weighted average shares outstanding, basic

-

-

9,552

7,505

-

-

4,652

4,652

-

-

8,874

5,350

-

-

1,112

874

-

-

5,813

5,667

4,245

-

3,743

3,671

-

-

99,156

90,645

-

Net loss per share, diluted

-

-

-0.73

-0.69

-

-

-0.60

-0.68

-

-

-0.09

-1.46

-

-

-3.23

-7.82

-

-

-0.30

-0.33

-3.49

-

3.30

2.09

-

-

-0.49

-0.16

-

Weighted average shares outstanding, diluted

-

-

9,552

7,720

-

-

4,652

4,652

-

-

8,874

5,519

-

-

1,112

876

-

-

5,813

7,545

4,245

-

6,319

6,497

-

-

99,156

90,645

-